PAIN RELIEVING DRUGS MARKET FORECAST 2014-2024
Future Prospects for Leading Companies

世界の鎮痛剤(痛み止め)市場予測:麻薬性鎮痛薬/非麻酔鎮痛薬/神経因性疼痛薬/抗片頭痛薬/抗関節炎薬

◆タイトル:PAIN RELIEVING DRUGS MARKET FORECAST 2014-2024
Future Prospects for Leading Companies
◆商品コード:VISG409041
◆調査・発行会社:visiongain
◆発行日:2014年9月
◆ページ数:323
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single user licence(1名使用)GBP1,799 ⇒換算¥266,252見積依頼/購入/質問フォーム
Dept Licence(部署内共有可)GBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site Licence(同一国内社内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界の鎮痛剤(痛み止め)市場予測:麻薬性鎮痛薬/非麻酔鎮痛薬/神経因性疼痛薬/抗片頭痛薬/抗関節炎薬"について調査・分析し、レポートサマリー、市場動向、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、市場環境分析、研究開発パイプライン分析、専門家の見解、結論などの情報をお届けいたします。

Pain relieving drugs – new study showing you trends, R&D progress, and predicted revenues
Where is the pain relieving drugs market heading? What are the commercial prospects for this market and related technologies? See what the future holds for painkillers. Visiongain’s new report shows you potential revenues and other trends to 2024, discussing data, opportunities and prospects.

Our 323 page report provides 265 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket and national level. You will see financial results, interviews, trends, opportunities and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and STEP), company profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
• Dr Stephen K Doberstein, Senior Vice President and Chief Scientific Officer, Nektar Therapeutics
• Dr Tom McCarthy, Chief Executive Officer, Spinifex Pharmaceuticals

You find prospects for key submarkets
In addition to analyses of the overall world market, you see revenue forecasts for these six submarkets to 2024:
• Narcotic pain relieving drugs
• Neuropathic pain relieving drugs
• Treatments for arthritis
• Non-Narcotic pain relieving drugs
• Treatments for migraines
• Other pain relieving drugs

Technologies that improve on the tolerance and dependence issues associated with pain relieving drugs will achieve success. The increasing use of abuse-resistant delivery systems in particular will be a major benefiting factor for pain relieving drugs as a whole.

Our investigation shows business research and analyses with individual revenue forecasts and discussions. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products
How will leading drugs perform to 2024 at the world level? Our study forecasts sales of 28 products including these brands:
• Celebrex
• Voltaren
• Relpax
• Lyrica
• Cymbalta
• Aspirin
• Zomig
• Duragesic
• Oxycontin ER
• Panadol
• Lidoderm

Our study includes OTC (over-the-counter) and Rx (prescription) pain relieving medicines.

Discover how high revenues can go. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects for the leading regions and countries?
Developments worldwide will influence the market, especially fast-rising demand in emerging countries. There will be many opportunities for pain-treating products.

In addition to analyses of the overall world market, you discover individual revenue forecasts for 13 national markets to 2024:
• US
• Japan
• Germany
• France
• UK
• Italy
• Spain
• Brazil
• Russia
• India
• China
• Turkey
• South Korea
• Rest of the World

【レポートの目次】

1. Report Overview
1.1 Global Pain Relieving Drugs: Market Overview
1.2 Global Pain Relieving Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. An Introduction to Pain and Pain Management
2.1 Pain: A Sensory And Emotional Phenomenon
2.1.1 Pain: A Short History
2.1.2 Pain Pathways And The Origin Of Pain
2.2 The World Health Organisation (WHO) Pain Ladder
2.2.1 Classification Of Pain
2.2.1.1 Acute Pain
2.2.1.2 Chronic Pain
2.3 The Psychosocial Effects Of Chronic Pain
2.3.1 Chronic Cancer Pain
2.3.2 Neuropathic Pain
2.3.3 Identifying Neuropathic Pain
2.4 The Neurochemistry Of Pain
2.4.1 Prostaglandins
2.4.2 Opioids
2.5 Pain Management – A Brief Overview
2.6 Pain Management Drugs
2.6.1 The Use Of Opioids In Pain Treatment
2.6.2 OTC Pain Relievers
2.7 Market Definition

3. World Pain Relieving Drugs Market 2014-2024
3.1 Global Pain Relieving Drugs: Market Overview
3.1.1 Categorisation of the Global Pain Relieving Drug Market
3.1.2 Pain Relieving Drugs: A Growing Market
3.2 The Global Pain Relieving Drugs Market in 2013
3.2.1 Market Dominance of Arthritic Pain Relieving Drugs
3.3 Global Pain Relieving Drugs: Market Forecast 2014-2024
3.3.1 Market Sectors That Will Drive Growth
3.3.2 Abuse Deterrents and Safety Measures Will Boost Narcotic Pain Relieving Drugs Market Growth
3.3.3 Changing Market Shares by Sector 2014-2024

4. Narcotic Pain Relieving Drugs: World Market Analysis and Forecast 2014-2024
4.1 The Global Narcotic Pain Relieving Drugs Market in 2013
4.1.1 Global Narcotic Pain Relieving Drugs: Market Forecast 2014-2024
4.1.2 Changing Market Shares By Leading Drugs 2014-2024
4.2 Opana ER (Endo Pharmaceuticals): Market Analysis
4.2.1 Tamper-Proof Opana ER Products
4.2.2 Opana ER: Historical Sales Analysis, 2014-2024
4.2.3 Opana ER: Sales Forecast 2014-2024
4.3 Duragesic: Market Analysis
4.3.1 Duragesic: Historical Sales Analysis, 2011-2013
4.3.2 Duragesic: Sales Forecast 2014-2024
4.4 Oxycontin ER: Market Analysis
4.4.1 Tamper Resistant Oxycontin ER
4.4.2 Oxycontin ER: Patent Expiries and Legal Battles
4.4.3 Oxycontin ER: Sales Forecast 2014-2024
4.5 Ultram: Market Analysis
4.5.1 Ultram: Sales Forecast 2014-2024
4.6 Zaldiar/Ixprim: Market Analysis
4.6.1 Zaldiar/Ixprim: Historical Sales Analysis, 2011-2013
4.6.2 Zaldiar/Ixprim: Sales Forecast 2014-2024
4.7 Other Narcotic Pain Relieving Drugs
4.7.1 Subsys (Insys Therapeutics)
4.7.2 Oxecta (Pfizer)
4.7.3 Other Narcotic Pain Relieving Drugs: Sales Forecast 2014-2024

5. Non-Narcotic Pain Relieving Drugs: World Market Analysis and Forecast 2014-2024
5.1 The Global Non-Narcotic Pain Relieving Drugs Market in 2013
5.1.1 Global Non-Narcotic Pain Relieving Drugs: Market Forecast 2014-2024
5.1.2 Changing Market Shares By Leading Drugs 2014-2024
5.2 Aspirin (Bayer): Market Analysis
5.2.1 Aspirin (Bayer): Historical Sales Analysis, 2010-2013
5.2.2 Aspirin (Bayer): Sales Forecast 2014-2024
5.3 Panadol: Market Analysis
5.3.1 Panadol: Historical Sales Analysis, 2008-2013
5.3.2 Panadol: Sales Forecast 2014-2024
5.4 Advil: Market Analysis
5.4.1 Advil: Historical Sales Analysis, 2012 and 2013
5.4.2 Advil: Sales Forecast 2014-2024
5.5 Tylenol: Market Analysis
5.5.1 Tylenol: Sales Forecast 2014-2024
5.6 Other Non-Narcotic Pain Drugs
5.6.1 Exparel (Pacira Pharmaceuticals)
5.6.2 Other Non-Narcotic Pain Drugs: Sales Forecast 2014-2024

6. Neuropathic Pain Relieving Drugs: World Market Analysis and Forecast 2014-2024
6.1 An Introduction to Neuropathic Pain
6.1.1 Identifying Neuropathic Pain
6.1.2 Pharmacological Interventions for Neuropathic Pain
6.1.2.1 Analgesics in Neuropathic Pain
6.1.2.2 Anti-Convulsants
6.1.2.3 Local Anaesthetics
6.1.2.4 Anti-Depressants
6.1.2.5 Aldose Reductase Inhibitors
6.1.3 The Global Neuropathic Pain Relieving Drugs Market in 2013
6.1.4 Global Neuropathic Pain Relieving Drugs: Market Forecast 2014-2024
6.1.5 Changing Market Shares By Leading Drugs 2014-2024
6.2 Lidoderm: Market Analysis
6.2.1 Lidoderm Patent Expiry and Endo Pharma – Watson/Actavis Agreement
6.2.2 Lidoderm Marketing Probe
6.2.3 Lidoderm: Historical Sales Analysis, 2009-2013
6.2.4 Lidoderm: Sales Forecast 2014-2024
6.3 Lyrica: Market Analysis
6.3.1 Lyrica: Historical Sales Analysis, 2009-2013
6.3.2 Lyrica: Sales Forecast 2014-2024
6.4 Cymbalta: Market Analysis
6.4.1 Cymbalta: Historical Sales Analysis, 2008-2013
6.4.2 Cymbalta: Sales Forecast 2014-2024
6.5 Neurontin: Market Analysis
6.5.1 Neurontin: Historical Sales Analysis, 2009-2013
6.5.2 Neurontin: Sales Forecast 2014-2024
6.6 Nucynta: Market Analysis
6.6.1 Nucynta: Historical Sales Analysis, 2011-2013
6.6.2 Nucynta: Sales Forecast 2014-2024
6.7 Other Neuropathic Pain Relieving Drugs
6.7.1 Retigabine (GSK; Valeant)
6.7.2 Other Neuropathic Pain Relieving Drugs: Sales Forecast 2014-2024

7. Anti-Migraine Drugs: World Market Analysis and Forecast 2014-2024
7.1 Migraine: An Introduction
7.1.1 Management of Migraine
7.1.2 Drugs Being Used In the Treatment of Migraine
7.1.3 Other Migraine Relieving Techniques
7.1.4 The Global Anti-Migraine Pain Relieving Drugs Market in 2013
7.1.5 Global Anti-Migraine Pain Relieving Drugs: Market Forecast 2014-2024
7.1.6 Changing Market Shares By Leading Drugs 2014-2024
7.2 Relpax: Market Analysis
7.2.1 Relpax: Historical Sales Analysis, 2009-2013
7.2.2 Relpax: Sales Forecast 2014-2024
7.3 Maxalt: Market Analysis
7.3.1 Maxalt: Historical Sales Analysis, 2008-2013
7.3.2 Maxalt: Sales Forecast 2014-2024
7.4 Imitrex/Imigran: Market Analysis
7.4.1 Imitrex/Imigran: Historical Sales Analysis, 2008-2013
7.4.2 Imitrex/Imigran: Sales Forecast 2014-2024
7.5 Zomig: Market Analysis
7.5.1 Zomig: Licensing Transfers and Exclusivity
7.5.2 Zomig: Historical Sales Analysis, 2009-2013
7.5.3 Zomig: Sales Forecast 2014-2024
7.6 Botox (Allergan): Market Analysis
7.6.1 Botox: Historical Sales Analysis, 2009-2013
7.6.2 Botox: Sales Forecast 2014-2024
7.7 Treximet: Market Analysis
7.7.1 Treximet: Agreements Between GSK, Pozen Pharmaceuticals and Pernix Therapeutics
7.7.2 The Generic Treats to Treximet
7.7.3 Treximet: Historical Sales Analysis, 2008-2013
7.7.4 Treximet: Sales Forecast 2014-2024
7.8 Axert: Market Analysis
7.8.1 Axert: Historical Sales Analysis, 2011-2013
7.8.2 Axert: Sales Forecast 2014-2024
7.9 Other Anti-Migraine Pain Relieving Drugs: Sales Forecast, 2014-2024
7.10 Anti-Migraine Pain Relieving Drugs Market – Future Prospects
7.10.1 Unmet Needs in the Treatment of Migraine

8. Anti-Arthritic Pain Drugs: World Market Analysis and Forecast 2014-2024
8.1 Understanding Arthritis: An Introduction to its Aetiology and Prevalence
8.1.1 Management of Arthritic Conditions
8.1.2 Drugs Being Used In The Treatment Of Arthritis
8.1.2.1 Analgesics As Pain Relieving Drugs
8.1.2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
8.1.2.3 Corticosteroids
8.1.2.4 Disease Modifying Anti-Rheumatic Drugs (DMARDS)
8.1.3 Biological Drugs in the Treatment Of Arthritis
8.1.3.1 Biologics Used for Rheumatoid Arthritis
8.1.3.2 The Potential Side Effects of Biologics in the Treatment of Arthritis
8.1.4 The Global Anti-Arthritis Pain Relieving Drugs Market in 2013
8.1.5 Global Anti-Arthritis Pain Relieving Drugs: Market Forecast 2014-2024
8.1.6 Changing Market Shares By Leading Drugs, 2014-2024
8.2 Humira: Market Analysis
8.2.1 Humira: Historical Sales Analysis, 2011-2013
8.2.2 Humira: Sales Forecast 2014-2024
8.3 Enbrel: Market Analysis
8.3.1 Enbrel: Co-Promotions and Marketing Rights
8.3.2 Enbrel: Historical Sales Analysis, 2008-2013
8.3.3 Enbrel: Patent Expiries and Potential Competition, 2014-2024
8.3.4 Enbrel: Sales Forecast 2014-2024
8.4 Remicade: Market Analysis
8.4.1 Remicade: Historical Sales Analysis, 2008-2013
8.4.2 Remicade: Patent Expiries and Potential Competition, 2014-2024
8.4.3 Remicade: Sales Forecast 2014-2024
8.5 Voltaren: Market Analysis
8.5.1 Voltaren: Historical Sales Analysis, 2008-2013
8.5.2 Voltaren: Sales Forecast 2014-2024
8.6 Rituxan (Rituximab, MabThera): Market Analysis
8.6.1 Rituxan: Historical Sales Analysis, 2008-2013
8.6.2 Rituxan: Patent Expiries and Potential Competition, 2014-2024
8.6.3 Rituxan: Sales Forecast 2014-2024
8.7 Celebrex: Market Analysis
8.7.1 Celebrex: Historical Sales Analysis, 2008-2013
8.7.2 Celebrex: Patents, Exclusivity, and Competition, 2014-2024
8.7.3 Celebrex: Sales Forecast 2014-2024
8.8 Arcoxia: Market Analysis
8.8.1 Arcoxia: Historical Sales Analysis, 2008-2013
8.8.2 Arcoxia: Sales Forecast 2014-2024
8.9 Other Anti-Arthritis Pain Relieving Drugs
8.9.1 Duexa (Horizon Pharma)
8.9.2 Lodotra/RAYOS (Horizon Pharma; SkyePharma)
8.9.3 Ofatumumab (Genmab, GSK)
8.9.4 Other Anti-Arthritis Pain Relieving Drugs: Sales Forecast 2014-2024
8.10 Anti-Arthritic Pain Relieving Drug Market – Future Prospects

9. Leading National Markets for Pain Relieving Drugs 2014-2024
9.1 The Pain Relieving Drug Market By Region
9.1.1 The Global Distribution of Pain Relieving Drugs In 2013
9.2 Leading National Markets: Forecast, 2014-2024
9.2.1 Changing Market Shares By Region, 2014-2024
9.3 Regional Pain Relieving Drugs Markets: Analysis and Forecasts, 2014-2024
9.4 United States: The Largest Pain Relieving Drug Market
9.5 The EU5 Markets
9.5.1 EU5 Markets: Changing Market Shares by Country, 2014-2024
9.5.2 Germany
9.5.3 UK
9.5.4 France
9.5.5 Italy
9.5.6 Spain
9.6 Japan
9.7 China
9.8 South Korea
9.9 Brazil
9.10 India
9.11 Russia
9.12 Turkey
9.13 Rest of the World

10. Pain Relieving Drugs: R&D Pipeline 2014-2024
10.1 Innovative Products Currently In Development Will Drive Growth
10.1.1 Large Developmental Pipelines Encouraged By High Potential Growth
10.2 Development Pipeline For Narcotic Pain Relieving Drugs, 2014
10.2.1 Remoxy (Durect, Pain Therapeutics, Pfizer)
10.2.2 MoxDuo IR (Shire; China Aoxing; QRxPharma)
10.2.3 ALO-02 (Pfizer)
10.2.4 DETERx – COL-003 (Collegium Pharmaceuticals)
10.2.5 Acurox (Acura; Pfizer)
10.2.6 Morphine-6-Glucuronide (Paion)
10.2.7 Acuracet (Acura)
10.2.8 ARX-02 (AcelRx Pharmaceuticals)
10.2.9 Zohydro ER (Zogenix)
10.2.10 BEMA Buprenorphine (BioDelivery Sciences; Endo Pharmaceuticals)
10.3 Development Pipeline For Non-Narcotic Pain Relieving Drugs, 2014
10.3.1 Lofexidine Hydrochloride (US World Meds)
10.3.2 Synera (Nuvo Research)
10.3.3 Neosaxitoxin (Proteus SA; Boston Children Hospital)
10.3.4 OMS103 (Omeros)
10.3.5 Tetrodotoxin (CK Life Sciences; WEX Pharmaceuticals)
10.4 Development Pipeline For Neuropathic Pain Relieving Drugs, 2014
10.4.1 Perampanel (Eisai)
10.4.2 Serenbotase (Syntaxin, Ipsen, Allergan)
10.4.3 EMA401 (Spinifex Pharmaceuticals)
10.4.4 Ralfinamide (Newron)
10.4.5 NT-11624 (Neurotune)
10.4.6 AmiKet (Immune Pharmaceuticals)
10.4.7 Eladur (Durect; Impax Laboratories)
10.4.8 Clonidine Gel (Arcion Therapeutics; BioDelivery Sciences)
10.4.9 AVP-923 (Avanir Pharmaceuticals)
10.4.10 ARC-2022 (Arcion Therapeutics)
10.5 Development Pipeline For Anti-Migraine Pain Relieving Drugs, 2014
10.5.1 Zecuity (NuPathe; Teva)
10.5.2 Lasmiditan (CoLucid Pharmaceuticals)
10.5.3 NXN-188 (NeurAxon)
10.5.4 Levadex/Semprana (Allergan)
10.6 Development Pipeline For Anti-Arthritis Pain Relieving Drugs, 2014
10.6.1 Zavryl/Ibuprofen-PC (PLx Pharma)
10.6.2 Naproxcinod (NicOx)
10.6.3 Xeljanz (Pfizer)
10.6.4 Masitinib (AB Science)
10.6.5 Belimumab (GSK, Human Genome Sciences)
10.7 What Does the Future Hold for Pain Relieving Drugs Research and Development?
10.8 Solubility: A Hindrance To Drug Development
10.9 Monoclonal Antibodies (MAbs) – Potential Novel Pain Drugs Facing Challenges
10.10 New Opioids Providing Opportunities For Growth
10.11 The Potential Use Of Cannabinoids In Pain Relief

11. Qualitative Analysis for the Global Pain Relieving Drugs Market 2014-2024
11.1 Market Factors Influencing The Pain Relieving Drugs Market
11.2 SWOT Analysis Of The Pain Relieving Drugs Market, 2014-2024
11.2.1 Strengths
11.2.1.1 Cost Effectiveness: A Major Driver for Growth
11.2.1.2 Promising Candidates In The R&D Pipeline
11.2.2 Weaknesses
11.2.2.1 Product Withdrawals And Slow Regulatory Approvals
11.2.2.2 Concerns Over Drug Side Effects
11.2.2.3 Education In Pain Management Is A Key Unmet Need
11.2.3 Opportunities
11.2.3.1 Reformulations Of Existing Drugs Will Drive Market Growth
11.2.3.2 Reforms In Narcotics Offer Growth Opportunities
11.2.3.3 Ageing Population – Growth Driver For Pain Relieving Drugs
11.2.3.4 The Economic Benefits Of Expansion Into Emerging Markets
11.2.3.5 OTC Switching May Help To Delay Generic Erosion
11.2.4 Threats
11.2.4.1 Patent Expiries Will Lead To Generic Competition
11.2.4.2 Regulatory And Pricing Scrutiny Could Suffocate Market Growth
11.2.4.3 Inadequate Reimbursement Levels: A Potential Restraint On Market Growth
11.3 STEP Analysis Of The Pain Relieving Drugs Market, 2014-2024
11.3.1 Social Factors Affecting The Pain Relieving Drugs Market
11.3.2 Technological Factors Affecting the Pain Relieving Drugs Market
11.3.3 Economic Factors Affecting The Pain Relieving Drugs Market
11.3.4 Political Factors Affecting The Pain Relieving Drugs Market

12. Expert Opinions
12.1 Interview With Dr Stephen K Doberstein, Senior Vice President And Chief Scientific Officer, Nektar Therapeutics
12.1.1 Pain Relieving Drugs: Current Trends In The Market
12.1.2 Nektar’s NKTR-181 Product And Its Mechanism To Mitigate Against Opioid Abuse
12.1.3 Key Developments In Pain Management And The Steps Being Taken To Reduce Addiction To Pain Drugs
12.1.4 Nektar’s Development Programme And Issues Around Penetration Of The Blood-Brain Barrier
12.1.5 Future Expansion Plans
12.1.6 On The Unmet Need For Abuse-Resistant And Highly Efficacious Pain Relieving Drugs
12.1.7 On The Developments Expected To Enter The Market In The Coming Years And The Need To Re-invent Known Classes Of Analgesic Molecules
12.2 Interview With Dr Tom McCarthy, Chief Executive Officer, Spinifex Pharmaceuticals
12.2.1 The Quest For Alternative Pain Relief Therapies
12.2.2 The Future Potential Of Combination Therapies In Pain Relief
12.2.3 On Developing, Validating and Demonstrating The Clinical Potential Of Novel Mechanisms For Tackling Pain
12.2.4 On The Market Potential Of Spinifex’s EMA401 Product
12.2.5 On Expansion Plans For EMA401 And Pain Relief As A Whole
12.2.6 The Drug Development And Commercialisation Challenges Facing The Pain Relieving Drugs Market
12.2.7 Future Outlook On The Market And The Potential For Novel Analgesics

13. Conclusions
13.1 Market Overview
13.2 The Likely Impacts Of Patent And Exclusivity Expiries On Pain Relieving Drugs
13.3 Major Growth Drivers For Pain Relieving Drugs
13.4 Under-Served Needs In Neuropathic Pain Leaves Room For Growth
13.5 The Narcotic Pain Relieving Drugs Market: Its Driving And Restraining Factors
13.6 Botox Approval Expected To Boost Anti-Migraine Submarket
13.7 The Rise Of Biological Anti-Arthritic Pain Drugs
13.8 Emerging Markets Set To Drive Steer Market Forward
13.9 What Does The Future Hold For Pain Relieving Drugs?



List of Tables
Table 1.1 Italian Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 1.2 Global Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2013-2024
Table 2.1 Comparison of Acute and Chronic Pain
Table 2.2 Therapeutic Classes In Pain Management
Table 3.1 The Global Pain Relieving Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2013
Table 3.2 The Global Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2013-2024
Table 3.3 The Global Pain Relieving Drugs Market Forecast: CAGR (%) by Sector, 2013-2018, 2018-2024, 2013-2024
Table 3.4 The Global Pain Relieving Drugs Market: Revenue ($m) by Sector, 2013, 2018, 2024
Table 3.5 The Global Pain Relieving Drugs Market: Market Share (%) by Sector, 2013, 2018, 2024
Table 4.1 The Global Narcotic Pain Relieving Drugs Market: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
Table 4.2 The Global Narcotic Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
Table 4.3 The Narcotic Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
Table 4.4 The Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
Table 4.5 Opana ER: Historical Sales ($m, AGR%), 2011-2013
Table 4.6 Opana ER: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 4.7 Duragesic: Historical Sales ($m, AGR%), 2011-2013
Table 4.8 Duragesic: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 4.9 Oxycontin: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 4.10 Ultram: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 4.11 Zaldiar/Ixprim: Historical Sales ($m, mEuros, AGR%), 2010-2013
Table 4.12 Zaldiar/Ixprim: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 4.13 Other Narcotic Pain Relieving Drugs: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.1 The Global Non-Narcotic Pain Relieving Drugs Market: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
Table 5.2 The Global Non-Narcotic Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
Table 5.3 The Non-Narcotic Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
Table 5.4 The Non-Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
Table 5.5 Aspirin and Aspirin Cardio: Historical Sales ($m, mEuros, AGR%), 2010-2013
Table 5.6 Aspirin (Bayer): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.7 Panadol Formulations, 2014
Table 5.8 Panadol (GSK): Historical Sales ($m, £m, AGR%), 2008-2013
Table 5.9 Panadol (GSK): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.10 Selected Advil Products and Product Details, 2014
Table 5.11 Advil: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.12 Selected Tylenol Products and Product Details, 2014
Table 5.13 Tylenol: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.14 Other Non-Narcotic Pain Drugs: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 6.1 Key Drug Indications for Neuropathic Pain, 2014
Table 6.2 FDA-Approved Drugs Indicated for Neuropathic Pain, 2014
Table 6.3 The Global Neuropathic Pain Relieving Drugs Market: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
Table 6.4 The Global Neuropathic Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
Table 6.5 The Neuropathic Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
Table 6.6 The Neuropathic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
Table 6.7 Lidoderm: Historical Sales ($m, AGR%), 2009-2013
Table 6.8 Lidoderm: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 6.9 Lyrica: Historical Sales ($m, AGR%), 2009-2013
Table 6.10 Lyrica: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 6.11 Cymbalta: Historical Sales ($m, AGR%), 2008-2013
Table 6.12 Cymbalta: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 6.13 Neurontin: Historical Sales ($m, AGR%), 2009-2013
Table 6.14 Neurontin: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 6.15 Nucynta: Historical Sales ($m, AGR%), 2010-2013
Table 6.16 Nucynta: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 6.17 Other Neuropathic Pain Relieving Drugs: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.1 The Global Anti-Migraine Pain Relieving Drugs Market: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
Table 7.2 The Global Anti-Migraine Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
Table 7.3 The Anti-Migraine Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
Table 7.4 The Anti-Migraine Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
Table 7.5 Relpax: Historical Sales ($m, AGR%), 2009-2013
Table 7.6 Relpax: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.7 Maxalt: Historical Sales ($m, AGR%), 2008-2013
Table 7.8 Maxalt: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.9 Imitrex/Imigran: Historical Sales ($m, £m, AGR%), 2008-2013
Table 7.10 Imitrex/Imigran: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.11 Zomig: Historical Sales ($m, AGR%), 2009-2013
Table 7.12 Zomig: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.13 Botox (Allergan): Historical Sales ($m, AGR%), 2009-2013
Table 7.14 Botox: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.15 Treximet: Historical Sales ($m, AGR%), 2008-2013
Table 7.16 Treximet: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.17 Axert: Historical Sales ($m, AGR%), 2011-2013
Table 7.18 Axert: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.19 Other Anti-Migraine Pain Relieving Drugs: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 8.1 Selected Examples of Anti-Arthritic Pain Relieving Drugs, 2014
Table 8.2 The Global Anti-Arthritic Pain Relieving Drugs Market: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
Table 8.3 The Global Anti-Arthritis Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
Table 8.4 The Anti-Arthritis Pain Relieving Drugs Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
Table 8.5 The Anti-Arthritis Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
Table 8.6 Humira: Historical Sales ($m, AGR%), 2010-2013
Table 8.7 Humira: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 8.8 Enbrel: Historical Sales ($m,bn Yen, AGR%) by Company, 2008-2013
Table 8.9 Enbrel: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 8.10 Remicade: Historical Sales ($m, bn Yen, AGR%) by Company, 2008-2013
Table 8.11 Remicade: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 8.12 Voltaren: Historical Sales ($m, AGR%), 2008-2013
Table 8.13 Voltaren: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 8.14 Rituxan: Historical Sales ($m, bn Yen, AGR%), 2008-2013
Table 8.15 Rituxan: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 8.16 Celebrex: Historical Sales ($m, AGR%), 2008-2013
Table 8.17 Celebrex: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 8.18 Arcoxia: Historical Sales ($m, AGR%), 2008-2013
Table 8.19 Arcoxia: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 8.20 Other Anti-Arthritis Pain Relieving Drugs: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.1 The Global Pain Relieving Drugs Market: Market Size ($m) and Market Share (%) by Region, 2013
Table 9.2 Global Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2013-2024
Table 9.3 Pain Relieving Drugs Market Forecast: CAGR (%) by Region, 2013-2018, 2018-2024, and 2013-2024
Table 9.4 Pain Relieving Drugs Market Forecast: Market Shares (%) by Region, 2013, 2018, 2024
Table 9.5 US Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.6 US Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.7 The EU5 Pain Relieving Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2013-2024
Table 9.8 The EU5 Pain Relieving Drugs Market: Revenue ($m) and Market Share (%) by Country, 2013
Table 9.9 EU5 Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.10 The EU5 Pain Relieving Drugs Market: Market Share (%) by Country, 2013, 2018, 2024
Table 9.11 The German Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.12 The German Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.13 The UK Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.14 The UK Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.15 French Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.16 French Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.17 Italian Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.18 Italian Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.19 Spanish Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.20 Spanish Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.21 Japanese Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.22 Japanese Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.23 Chinese Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.24 Chinese Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.25 South Korean Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.26 South Korean Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.27 Brazilian Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.28 Brazilian Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.29 Indian Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.30 Indian Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.31 Russian Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.32 Russian Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.33 Turkish Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.34 Turkish Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.35 Rest of the World Pain Relieving Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 9.36 Rest of the World Pain Relieving Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 10.1 R&D Pipeline for Narcotic Pain Relieving Drugs, 2014
Table 10.2 R&D Pipeline for Non-Narcotic Pain Relieving Drugs, 2014
Table 10.3 R&D Pipeline for Neuropathic Pain Relieving Drugs, 2014
Table 10.4 R&D Pipeline for Anti-Migraine Pain Relieving Drugs, 2014
Table 10.5 R&D Pipeline for Anti-Arthritis Pain Relieving Drugs, 2014
Table 11.1 Pain Relieving Drugs: Market Drivers and Restraints 2014-2024
Table 11.2 SWOT Analysis of the Pain Relieving Drugs Market, 2014-2024
Table 11.3 Global Population Forecast: Total Population (bn, CAGR %) and Over-65 Population (bn, CAGR%), 2012, 2015, 2018, 2023
Table 11.4 STEP Analysis of the Pain Relieving Drugs Market, 2014-2024
Table 13.1 Pain Relieving Drugs: Market Forecast ($m, CAGR%), 2013, 2018, 2021, 2024
Table 13.2 Pain Relieving Drugs: Market Forecast ($m) by Sector, 2013, 2018, 2021, 2024
Table 13.3 Global Pain Relieving Drugs: Market Shares (%) by Region, 2013, 2018, 2021, 2024

★調査レポート[世界の鎮痛剤(痛み止め)市場予測:麻薬性鎮痛薬/非麻酔鎮痛薬/神経因性疼痛薬/抗片頭痛薬/抗関節炎薬] ( PAIN RELIEVING DRUGS MARKET FORECAST 2014-2024
Future Prospects for Leading Companies / VISG409041) 販売に関する免責事項
[世界の鎮痛剤(痛み止め)市場予測:麻薬性鎮痛薬/非麻酔鎮痛薬/神経因性疼痛薬/抗片頭痛薬/抗関節炎薬] ( PAIN RELIEVING DRUGS MARKET FORECAST 2014-2024
Future Prospects for Leading Companies / VISG409041) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆